Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.66 USD | -0.51% |
|
+9.46% | -25.78% |
17/06 | Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target | MT |
03/06 | Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.78% | 8.18B | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating